EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells
暂无分享,去创建一个
[1] V. Syed,et al. TGF‐β Signaling in Cancer , 2016, Journal of cellular biochemistry.
[2] F. Jiao,et al. EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer , 2016, Oncotarget.
[3] Stefan Enroth,et al. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target , 2016, Oncotarget.
[4] T. Jiang,et al. Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis , 2015, Oncotarget.
[5] B. Klein,et al. EZH2 in normal hematopoiesis and hematological malignancies , 2015, Oncotarget.
[6] Eran Meshorer,et al. Chromatin remodeling and bivalent histone modifications in embryonic stem cells , 2015, EMBO reports.
[7] J. Pritchard,et al. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors , 2015, Oncotarget.
[8] R. Paro,et al. Trithorax and Polycomb group-dependent regulation: a tale of opposing activities , 2015, Development.
[9] M. Harmsen,et al. Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22α expression in endothelial cells in response to interleukin-1β and transforming growth factor-β2. , 2015, Cellular signalling.
[10] Aaron T. L. Lun,et al. Repression of Igf1 expression by Ezh2 prevents basal cell differentiation in the developing lung , 2015, Development.
[11] C. Kang,et al. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. , 2015, Cancer letters.
[12] P. Papageorgis. TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis , 2015, Journal of oncology.
[13] Pierre-Olivier Angrand,et al. Diverse involvement of EZH2 in cancer epigenetics. , 2015, American journal of translational research.
[14] Amanda E. Jones,et al. Snail2/Slug cooperates with Polycomb repressive complex 2 (PRC2) to regulate neural crest development , 2015, Development.
[15] G. Jayandharan,et al. Ezh2 mediated H3K27me3 activity facilitates somatic transition during human pluripotent reprogramming , 2015, Scientific Reports.
[16] P. Angrand,et al. Diverse involvement of EZH 2 in cancer epigenetics , 2015 .
[17] D. Matei,et al. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells , 2014, Epigenetics.
[18] K. Sundfeldt,et al. TGF-β isoforms induce EMT independent migration of ovarian cancer cells , 2014, Cancer Cell International.
[19] A. Díaz-López,et al. A core microRNA signature associated with inducers of the epithelial‐to‐mesenchymal transition , 2014, The Journal of pathology.
[20] H. Aburatani,et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders , 2013, The Journal of experimental medicine.
[21] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[22] C. Plass,et al. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer , 2013, Nature Reviews Genetics.
[23] J. Jonkers,et al. Polycomb group gene Ezh2 regulates mammary gland morphogenesis and maintains the luminal progenitor pool , 2013, Stem cells.
[24] Robert A. Weinberg,et al. Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity , 2013, Cell.
[25] Y. Shang,et al. Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. , 2013, Experimental cell research.
[26] M. Loda,et al. EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.
[27] Cun-Yu Wang,et al. Histone Demethylase KDM6B Promotes Epithelial-Mesenchymal Transition* , 2012, The Journal of Biological Chemistry.
[28] Yan Liu,et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.
[29] Christopher J. Schofield,et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response , 2012, Nature.
[30] C. Heldin,et al. Regulation of EMT by TGFβ in cancer , 2012, FEBS letters.
[31] D. Matei,et al. Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer , 2012, Oncogene.
[32] R. Yang,et al. Global mapping of H3K4me3 and H3K27me3 reveals chromatin state-based regulation of human monocyte-derived dendritic cells in different environments , 2012, Genes and Immunity.
[33] S. Baylin,et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. , 2011, Cancer cell.
[34] Qiang Yu,et al. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. , 2011, Molecular cell.
[35] A. Feinberg,et al. Genome-scale epigenetic reprogramming during epithelial to mesenchymal transition , 2011, Nature Structural &Molecular Biology.
[36] Q. Cai,et al. Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer Cells , 2010, Molecular Cancer Research.
[37] Y. Zeng,et al. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. , 2010, Carcinogenesis.
[38] R. Kuiper,et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.
[39] R. Huang,et al. Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.
[40] Tracey M. Filzen,et al. Tumorigenesis and Neoplastic Progression Targeted Overexpression of EZH 2 in the Mammary Gland Disrupts Ductal Morphogenesis and Causes Epithelial Hyperplasia , 2010 .
[41] S. Dhanasekaran,et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.
[42] C. Sturgis,et al. Transforming Growth Factor-β1, Transforming Growth Factor-β2, and Transforming Growth Factor-β3 Enhance Ovarian Cancer Metastatic Potential by Inducing a Smad3-Dependent Epithelial-to-Mesenchymal Transition , 2008, Molecular Cancer Research.
[43] T. Veenstra,et al. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases , 2007, Proceedings of the National Academy of Sciences.
[44] M. Fraga,et al. The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.
[45] Gema Moreno-Bueno,et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. , 2006, Cancer research.
[46] S. Ramaswamy,et al. Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.
[47] Yi Zhang,et al. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. , 2004, Current opinion in genetics & development.
[48] K. Sundfeldt. Cell–cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule , 2003, Molecular and Cellular Endocrinology.
[49] J. Thiery. Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.
[50] R. Derynck,et al. TGF-β signaling in cancer – a double-edged sword , 2001 .
[51] G. Berx,et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. , 2001, Molecular cell.
[52] R. Derynck,et al. TGF-beta signaling in cancer--a double-edged sword. , 2001, Trends in cell biology.
[53] C. Marth,et al. Regulation of transforming growth factor-beta secretion by human peritoneal mesothelial and ovarian carcinoma cells. , 2000, Cytokine.
[54] K. Yasuda,et al. Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA , 1987, Nature.